Dr. Anwaar Saeed
Claim this profileUniversity of Kansas Cancer Center
Studies Colorectal Cancer
Studies Stomach Cancer
20 reported clinical trials
37 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
PD-L1 positive
2Stomach Cancer
Stage IV
Stage III
MSI negative
Affiliated Hospitals
Clinical Trials Anwaar Saeed is currently running
OBT076
for Advanced Cancer
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
More about Anwaar Saeed
Clinical Trial Related3 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Anwaar Saeed has experience with
- Atezolizumab
- Durvalumab
- Oxaliplatin
- Tremelimumab
- 9-ING-41
- Gemcitabine
Breakdown of trials Anwaar Saeed has run
Colorectal Cancer
Stomach Cancer
Skin Cancer
Liver Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anwaar Saeed specialize in?
Anwaar Saeed focuses on Colorectal Cancer and Stomach Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Anwaar Saeed currently recruiting for clinical trials?
Yes, Anwaar Saeed is currently recruiting for 8 clinical trials in Westwood Kansas. If you're interested in participating, you should apply.
Are there any treatments that Anwaar Saeed has studied deeply?
Yes, Anwaar Saeed has studied treatments such as Atezolizumab, Durvalumab, Oxaliplatin.
What is the best way to schedule an appointment with Anwaar Saeed?
Apply for one of the trials that Anwaar Saeed is conducting.
What is the office address of Anwaar Saeed?
The office of Anwaar Saeed is located at: University of Kansas Cancer Center, Westwood, Kansas 66205 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.